Johnson & Johnson is preparing next year to spin off its consumer health unit into a publicly traded company separate from its pharmaceutical and medical technology operations. Ahead of the split, Morgan Stanley put out a research note, highlighting some of the debates in the market over the move, which would result in a consumer brands company called Kenvue and a pharma company with the J & J moniker.
The company's approved and pending treatments for blood cancer and multiple myeloma are "underappreciated," Morgan Stanley said. The analysts added that the multiple myeloma market will grow to about $33 billion in 2030 — and by that time, J & J's therapies could take more than 80% of that market share.
Interesting...
will they both be called Johnson?
Is this to dodge the up and coming lawsuits?
South Africa South Africa Latest News, South Africa South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: WSJ - 🏆 98. / 63 Read more »
Source: CNBC - 🏆 12. / 72 Read more »